Danaher Corporation $DHR Shares Purchased by State of Alaska Department of Revenue

State of Alaska Department of Revenue increased its position in Danaher Corporation (NYSE:DHR) by 285.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 237,740 shares of the conglomerate’s stock after purchasing an additional 176,020 shares during the period. State of Alaska Department of Revenue’s holdings in Danaher were worth $52,671,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DHR. Veery Capital LLC increased its stake in Danaher by 3.1% during the 3rd quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock valued at $350,000 after purchasing an additional 48 shares in the last quarter. Studio Investment Management LLC lifted its stake in shares of Danaher by 3.3% in the second quarter. Studio Investment Management LLC now owns 1,581 shares of the conglomerate’s stock worth $302,000 after buying an additional 51 shares in the last quarter. JDH Wealth Management LLC lifted its stake in shares of Danaher by 4.5% in the first quarter. JDH Wealth Management LLC now owns 1,264 shares of the conglomerate’s stock worth $240,000 after buying an additional 55 shares in the last quarter. OLD Second National Bank of Aurora grew its holdings in shares of Danaher by 0.5% during the first quarter. OLD Second National Bank of Aurora now owns 12,114 shares of the conglomerate’s stock valued at $2,297,000 after buying an additional 57 shares during the last quarter. Finally, Adelphi Trust Co grew its holdings in shares of Danaher by 2.5% during the third quarter. Adelphi Trust Co now owns 2,365 shares of the conglomerate’s stock valued at $524,000 after buying an additional 57 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Trading Up 3.0%

Shares of DHR stock opened at $231.52 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market cap of $162.76 billion, a price-to-earnings ratio of 41.12, a PEG ratio of 2.82 and a beta of 0.76. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80. The firm has a fifty day moving average price of $213.55 and a 200-day moving average price of $195.74.

Danaher (NYSE:DHR) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping analysts’ consensus estimates of $1.85 by $0.09. The company had revenue of $6.26 billion for the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a return on equity of 11.04% and a net margin of 15.95%. Danaher’s revenue for the quarter was up 5.5% compared to the same quarter last year. During the same period last year, the firm earned $0.77 EPS. As a group, equities analysts predict that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a $0.40 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. Danaher’s dividend payout ratio (DPR) is 28.42%.

Wall Street Analyst Weigh In

DHR has been the subject of several analyst reports. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and set a $240.00 price target on shares of Danaher in a research report on Wednesday, July 22nd. The Goldman Sachs Group boosted their price objective on shares of Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Wells Fargo & Company lowered their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 22nd. Stifel Nicolaus cut their target price on Danaher from $260.00 to $220.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Finally, Royal Bank Of Canada lifted their target price on Danaher from $215.00 to $250.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $235.41.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

About Danaher

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.